Local:
Absorption: Well absorbed after administration into the deltoid muscle; some absorption follows local use.
Distribution: Widely distributed. Concentrates in adipose tissue. Crosses the blood-brain barrier and placenta; enters breast milk.
Metabolism/Excretion: Mostly metabolized by the liver; <10% excreted in urine as unchanged drug.
Half-life: Biphasic initial phase, 730 min; terminal phase, 90120 min; ↑ in HF and liver impairment.
Contraindicated in:
Use Cautiously in:
CV: CARDIAC ARREST, arrhythmias, bradycardia, heart block, hypotension.
EENT: mucosal use: ↓or absent gag reflex.
GI: nausea, vomiting.
Hemat: methemoglobinemia.
Local: stinging, burning, contact dermatitis, erythema.
MS: chondrolysis.
Neuro: paresthesia, tremor , SEIZURES, confusion, drowsiness, agitation, blurred vision, dizziness, slurred speech.
Resp: bronchospasm.
Drug-Drug:
Ventricular Tachycardia (with a Pulse) or Pulseless Ventricular Tachycardia/Ventricular Fibrillation
Local
IV Administration:
lidocaine (Parenteral): Xylocaine
lidocaine (Local Anesthetic): Xylocaine
lidocaine (Mucosal): Xylocaine Viscous
Lidocaine (Transdermal): Lidoderm, ZTLido
lidocaine (Topical): Glydo, L-M-X 4, L-M-X 5, Xylocaine
lidocaine (Parenteral): Xylocard
lidocaine (Mucosal): Jampocaine Viscous
lidocaine (Topical): Betacaine, Cathejell, Lidodan, Lyracaine, Maxilene, Stallion, Topicaine
(Generic available)
(IV, IM = antiarrhythmic effects; local = anesthetic effects)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
IV | immediate | immediate | 1020 min (up to several hrs after continuous infusion) |
IM | 515 min | 2030 min | 6090 min |
Local | rapid | unknown | 13 hr |
NDC Code*